-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cenegermin in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cenegermin in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cenegermin in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Cenegermin (Oxervate)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cenegermin in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cenegermin in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cenegermin in Sicca Syndrome (Sjogren) Drug Details: Cenegermin (Oxervate) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Chronic Bronchitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tozorakimab in Chronic Bronchitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tozorakimab in Chronic Bronchitis Drug Details: Tozorakimab (MEDI-3506) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Reparixin in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Reparixin in Community Acquired Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Reparixin in Community Acquired Pneumonia Drug Details: Reparixin (Repertaxin) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Reparixin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Reparixin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Reparixin in Triple-Negative Breast Cancer (TNBC) Drug Details: Reparixin (Repertaxin)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Reparixin in Acute Respiratory Distress Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Reparixin in Acute Respiratory Distress Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Reparixin in Acute Respiratory Distress Syndrome Drug Details: Reparixin (Repertaxin)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cenegermin in Keratoconjunctivitis Sicca (Dry Eye)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cenegermin in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Cenegermin (Oxervate) is a recombinant human nerve...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFL-24412 in Chronic Low Back Pain (CLBP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFL-24412 in Chronic Low Back Pain (CLBP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFL-24412 in Chronic Low Back Pain (CLBP) Drug Details:...
-
Product Insights
Liver Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Liver Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pancreatic Islet Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Pancreatic Islet Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Pancreatic Islet Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatic Islet Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...